X
Xue-Ning Yang
Researcher at Peking Union Medical College
Publications - 148
Citations - 3983
Xue-Ning Yang is an academic researcher from Peking Union Medical College. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 25, co-authored 130 publications receiving 2729 citations. Previous affiliations of Xue-Ning Yang include Sun Yat-sen University & Guangdong General Hospital.
Papers
More filters
Journal ArticleDOI
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Zhong-Yi Dong,Zhong-Yi Dong,Wen-Zhao Zhong,Xu-Chao Zhang,Jian Su,Zhi Xie,Si-Yang Liu,Hai-Yan Tu,Hua-Jun Chen,Yue-Li Sun,Qing Zhou,Jin-Ji Yang,Xue-Ning Yang,Jia-Xin Lin,Hong-Hong Yan,Hao-Ran Zhai,Hao-Ran Zhai,Li-Xu Yan,Ri-Qiang Liao,Si-Pei Wu,Yi-Long Wu,Yi-Long Wu +21 more
TL;DR: Evidence is provided that TP53 and KRAS mutation in lung adenocarcinoma may be served as a pair of potential predictive factors in guiding anti-PD-1/PD-L1 immunotherapy.
Journal ArticleDOI
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Wen-Zhao Zhong,Qun Wang,Weimin Mao,Song-Tao Xu,Lin Wu,Yi Shen,Yongyu Liu,Chun Chen,Ying Cheng,Lin Xu,Jun Wang,Ke Fei,Xiaofei Li,Jian Li,Cheng Huang,Zhidong Liu,Shun Xu,Ke-Neng Chen,Shidong Xu,Lunxu Liu,Ping Yu,Bu-Hai Wang,H. Ma,Hong-Hong Yan,Xue-Ning Yang,Qing Zhou,Yi-Long Wu,Siyu Wang,Jian Hu,Wei Liu,Wei Li,Jianhua Shi +31 more
TL;DR: Adjuvant gefitinib led to significantly longer disease-free survival compared with that for vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant NSCLC.
Journal ArticleDOI
Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
Xu-Chao Zhang,Shirley Zhang,Xue-Ning Yang,Jin-Ji Yang,Qing Zhou,Lucy Yin,She-Juan An,Jiaying Lin,Shiliang Chen,Zhi Zhou Xie,Mike Zhu,Xiaolin Zhang,Yi-Long Wu +12 more
TL;DR: In this article, the anaplastic lymphoma kinase (ALK) gene is frequently involved in translocations that lead to gene fusions in a variety of human malignancies, including lymphoma and lung cancer.
Journal ArticleDOI
Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer
Qing Zhou,Xu-Chao Zhang,Zhi-Hong Chen,Xiao-Lu Yin,Jin-Ji Yang,Chong-Rui Xu,Hong-Hong Yan,Hua-Jun Chen,Jian Su,Wen-Zhao Zhong,Xue-Ning Yang,She-Juan An,Bin-Chao Wang,Yi-Sheng Huang,Zhen Wang,Yi-Long Wu +15 more
TL;DR: The relative EGFR mutation abundance could predict benefit from EGFR-TKI treatment for advanced NSCLC and the difference between patients with high and low abundances of EGFR mutations was not significant regarding ORR and OS.
Journal ArticleDOI
Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study
Wen-Zhao Zhong,Ke-Neng Chen,Chun Chen,Chun-Dong Gu,Jun Wang,Xue-Ning Yang,Weimin Mao,Qun Wang,Gui-bin Qiao,Ying Cheng,Lin Xu,Changli Wang,Mingwei Chen,Xiaozheng Kang,Wanpu Yan,Hong-Hong Yan,Ri-Qiang Liao,Jin-Ji Yang,Xu-Chao Zhang,Qing Zhou,Yi-Long Wu +20 more
TL;DR: The primary end point of ORR with 42 days of neoadjuvant erlotinib was not met, but the secondary end point PFS was significantly improved, which reflected those most commonly seen with the two treatments.